U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H17ClFN3O2S
Molecular Weight 441.906
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MK-4409

SMILES

CC(C)(O)C1=NC=C(C=C1)C2=C(OC(=N2)C3=CC=C(F)C=C3)SC4=NC=C(Cl)C=C4

InChI

InChIKey=DBZMCSVIITXLCC-UHFFFAOYSA-N
InChI=1S/C22H17ClFN3O2S/c1-22(2,28)17-9-5-14(11-25-17)19-21(30-18-10-6-15(23)12-26-18)29-20(27-19)13-3-7-16(24)8-4-13/h3-12,28H,1-2H3

HIDE SMILES / InChI

Molecular Formula C22H17ClFN3O2S
Molecular Weight 441.906
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 11:45:52 GMT 2023
Edited
by admin
on Sat Dec 16 11:45:52 GMT 2023
Record UNII
77GX6MU9ZL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MK-4409
Common Name English
2-PYRIDINEMETHANOL, 5-(5-((5-CHLORO-2-PYRIDINYL)THIO)-2-(4-FLUOROPHENYL)-4-OXAZOLYL)-.ALPHA.,.ALPHA.-DIMETHYL-
Systematic Name English
5-(5-((5-CHLORO-2-PYRIDINYL)THIO)-2-(4-FLUOROPHENYL)-4-OXAZOLYL)-.ALPHA.,.ALPHA.-DIMETHYL-2-PYRIDINEMETHANOL
Systematic Name English
Code System Code Type Description
FDA UNII
77GX6MU9ZL
Created by admin on Sat Dec 16 11:45:52 GMT 2023 , Edited by admin on Sat Dec 16 11:45:52 GMT 2023
PRIMARY
CAS
1207745-58-1
Created by admin on Sat Dec 16 11:45:52 GMT 2023 , Edited by admin on Sat Dec 16 11:45:52 GMT 2023
PRIMARY
WIKIPEDIA
MK-4409
Created by admin on Sat Dec 16 11:45:52 GMT 2023 , Edited by admin on Sat Dec 16 11:45:52 GMT 2023
PRIMARY MK-4409 is a drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 11 nM, and both analgesic and antiinflammatory effects in animal studies. It was developed for the treatment of neuropathic pain and has progressed as far as early stage human clinical trials.
EPA CompTox
DTXSID101045923
Created by admin on Sat Dec 16 11:45:52 GMT 2023 , Edited by admin on Sat Dec 16 11:45:52 GMT 2023
PRIMARY
PUBCHEM
53341130
Created by admin on Sat Dec 16 11:45:52 GMT 2023 , Edited by admin on Sat Dec 16 11:45:52 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Originator: Merck & Co; Class: Analgesic, Oxazole; Mechanism of Action: Fatty acid amide hydrolase inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: No development for reported Pain; Most Recent Events: 27 May 2016 Chemical information added, 15 Jul 2009 Phase-I clinical trials in Pain in USA (unspecified route)
ACTIVE MOIETY
Rat PK data on FAAH inhibitor MK-4409: AUCNpo d ((.MU.M h kg)/mg) = 2.2; half-life(h) = 4.3; Vd Cl (mL/minundefinedkg) = 20; Vd (L/kg) = 6.2; Vd F (%)e = 120; CFA Data Key for MK-4409: a Oral dose in mg/kg. = 10; % reversal of allodyniab 1 h time point = 49; % reversal of allodynia 3 h time point = 51; In Vitro Data of MK-4409: human FAAH lysate IC50 (nM) = 11; RatFAAH lysate IC50 (nM) = 11; MK-499 binding assay, Ki,(nM) = 1254; human VMAT EC50 (nM) = >20000